Impact of MDR-1 Gene Polymorphism (rs1128503) on Response to Imatinib or Nilotinib in Iraqi Patients with Chronic Myeloid Leukemia: An Observational Study

Ekhlas Khammas Hasan; Ali Abdulhussain Kasim; Bassam Francis Matti

doi:10.54133/ajms.v6i1.608

المؤلفون

Ekhlas Khammas Hasan Department of Clinical Pharmacy, College of Pharmacy, Al-Bayan University, Baghdad, Iraq; Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq
Ali Abdulhussain Kasim Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad https://orcid.org/0000-0003-0674-0969
Bassam Francis Matti Hematology and Bone Marrow Transplant Center, Medical City, Baghdad, Iraq https://orcid.org/0009-0009-6981-7426

DOI:

https://doi.org/10.54133/ajms.v6i1.608

الكلمات المفتاحية:

BCR-ABL fusion gene، Chronic myeloid leukemia، Imatinib، Nilotinib، MDR-1 gene

الملخص

Background: There is a significant molecular response to imatinib given at standard doses in individuals with chronic myeloid leukemia (CML) whose ABCB1 polymorphisms are present. Objective: To investigate the impact of the polymorphism in the ABCB1 gene rs1128503 on the effectiveness of nilotinib or imatinib therapy. Methods: From May 2022 until the end of January 2023, the current study was carried out in a single research institution, the National Center of Hematology, Baghdad Teaching Hospital at Medical City, Iraq. 76 people with chronic phase myeloid leukemia (CML-CP), who had previously received a diagnosis using the European Leukemia Net (ELN) criteria, enrolled in the trial. The PCR product was delivered to Macrogen Corporation, Korea, for Sanger sequencing on an automated DNA sequencer, the ABI3730XL. After receiving the results by email, Geneious Prime software was used for analysis. Results: Patients receiving imatinib or nilotinib did not differ significantly in terms of age or gender. In contrast, BCR-ABL1 transcript levels were considerably greater at sampling in patients receiving nilotinib. Different types of the MDR-1 gene rs1128503 genotype were not found in groups that were treated with either imatinib or nilotinib. Conclusions: BCR-ABL1 transcript levels are lower in patients still receiving imatinib than in those receiving nilotinib.

التنزيلات

بيانات التنزيل غير متوفرة بعد.

المراجع

L’Abbate A, Moretti V, Pungolino E, Micheloni G, Valli R, Frattini A, et al. Occurrence of L1M elements in chromosomal rearrangements associated to chronic myeloid leukemia (CML): Insights from patient-specific breakpoints characterization. Genes. 2023;14(7):1351. doi: 10.3390/genes14071351.

Rittavee Y, Artus J, Desterke C, Simanic I, de Souza LEB, Riccaldi S, et al. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells. Exp Hematol. 2023;118:40-52. doi: 10.1016/j.exphem.2022.12.003.

Abdulmawjood B, Costa B, Roma-Rodrigues C, Baptista PV, Fernandes AR. Genetic biomarkers in chronic myeloid leukemia: what have we learned so far? Int J Mol Sci. 2021;22(22):12516. doi: 10.3390/ijms222212516.

Hussein SA, Adnan M. The effect of PDE-5 inhibitors on blood homeostasis in relation to the type & duration of therapy. Int J Security Netw. 2015;6(1):28-35. doi: 10.1002/14651858.CD013507.

Khaleel AW, Altaee MF. Ltb4r gene expression in chronic myeloid leukemia in Iraq. Iraqi J Sci. 2023;64(5):2202-2014. doi: 10.24996/ijs.2023.64.5.9.

Aljoubory HM, Altaee MF. Correlation study between three different genes expression and chronic myeloid leukemia in Iraq. Iraqi J Agricult Sci. 2021;52(3). doi: 10.36103/ijas.v52i3.1350.

Osman AEG, Deininger MW. Chronic myeloid leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825. doi: 10.1016/j.blre.2021.100825.

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691-709. doi: 10.1002/ajh.25792.

Moustafa MM, Al-Janabi RD. Association of age, parity and body mass index with hemoglobin and serum ferritin levels in pregnant women in Baghdad city. Iraqi J Pharm Sci. 2021;30(2):153-157. doi: 10.31351/vol30iss2pp153-157.

Ali ZM, Ali SH, Mohsen FY. Assessment of some hematological parameters in Iraqi women with different breast cancer stages. Iraqi J Pharm Sci. 2020;29(2):99-106. doi: 10.31351/vol29iss2pp99-106.

Hassan EF, Kadhim DJ, Younus MM. Safety profile of biological drugs in clinical practice: a retrospective pharmacovigilance study. Iraqi J Pharm Sci. 2022;31(1):32-42. doi: 10.31351/vol31iss1pp32-42.

Hassan AF, Al-Shawi NN, Salih MK, Ali PRMH, Hasan BOF. Cancer cells resistance strategies. Indian J Forensic Med Toxicol. 2021;15(1):791-797. doi: 10.37506/ijfmt.v15i1.13512.

De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, Soverini S. Overcoming resistance to kinase inhibitors: the paradigm of chronic myeloid leukemia. OncoTargets Ther. 2022:103-116. doi: 10.2147/OTT.S289306.

Abdul-Razq MH, Al-Amili WA, Al-Faisal AM, Abdulhassan IA, Jumaah SS. Influence of multi-drug transporter gene ABCG2 polymorphism (C421A) in clinical out care in some Iraqi chronic myeloid leukemia patients treated with imatinib mesylate. Iraqi J Biotechnol. 2017;16(3):98-107.

Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MWN, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leukemia Res. 2014;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011.

Soverini S, De Benedittis C, Mancini M, Martinelli G. Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia. Clin Lymphoma Myeloma Leukemia. 2015;15:S120-S128. doi: 10.1016/j.clml.2015.02.035.

Lyczek A, Berger BT, Rangwala AM, Paung Y, Tom J, Philipose H, et al. Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. Proc Natl Acad Sci USA. 2021;118(46):e2111451118. doi: 10.1073/pnas.2111451118.

Eadie LN, Hughes TP, White DL. Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia. 2018;32(10):2288-2291. doi: 10.1038/s41375-018-0101-5.

White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 2012;97(6):907. doi: 10.3324/haematol.2011.056457.

Reis FR, Vasconcelos FC, PeReIra DL, Moellman-Coelho A, Silva KL, Maia RC. Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep. 2011;26(2):471-478. doi: 10.3892/or.2011.1857.

Mancini M, De Santis S, Monaldi C, Bavaro L, Martelli M, Castagnetti F, et al. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. J Exp Clin Cancer Res. 2019;38(1):1-11. doi: 10.1186/s13046-019-1197-9.

Mancini M, Castagnetti F, Soverini S, Leo E, De Benedittis C, Gugliotta G, et al. FOXM1 transcription factor: a new component of chronic myeloid leukemia stem cell proliferation advantage. J Cell Biochem. 2017;118(11):3968-3975. doi: 10.18632/oncotarget.21166.

Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, et al. A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. 2016;30(7):1493-1501. doi: 10.1038/leu.2016.51.

Wu ZX, Yang Y, Wang JQ, Zhou WM, Chen J, Fu YG, et al. Elevated ABCB1 expression confers acquired resistance to aurora kinase inhibitor GSK-1070916 in cancer cells. Front Pharmacol. 2021;11:615824. doi: 10.3389/fphar.2020.615824.

Lei ZN, Teng QX, Wu ZX, Ping FF, Song P, Wurpel JND, et al. Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. MedComm. 2021;2(4):765-777. doi: 10.1002/mco2.106.

Abdulkareem RA, Rafaa TA, Jasim HA, Suleiman AAJ. Pharmacokinetic effect of MDR gene polymorphism rs2032582 on the therapeutic response in Iraqi patients with acute myeloid leukemia. Avicenna J Med Biotechnol. 2020;12(4):241.

Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112(5):2024-2027. doi: 10.1182/blood-2008-03-147744.

Nath A, Wang J, Stephanie Huang R. Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol Diag Ther. 2017;21(6):621-631. doi: 10.1007/s40291-017-0292-x.

Loscocco F, Visani G, Ruzzo A, Bagaloni I, Fuligni F, Galimberti S, et al. Clinical relevance of ABCB1, ABCG2, and ABCC2 gene polymorphisms in chronic myeloid leukemia patients treated with nilotinib. Front Oncol. 2021;11:672287. doi: 10.3389/fonc.2021.672287.

Dalle Fratte C, Polesel J, Gagno S, Posocco B, De Mattia E, Roncato R, et al. Impact of ABCG2 and ABCB1 polymorphisms on imatinib plasmatic exposure: An original work and meta-analysis. Int J Mol Sci. 2023;24(4):3303. doi: 10.3389/fonc.2021.672287.

Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi: 10.1016/S0140-6736(07)61602-X.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884. doi: 10.1182/blood-2013-05-501569.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84. doi: 10.1038/s41375-020-0776-2.

Au A, Baba AA, Azlan H, Norsa'adah B, Ankathil R. Clinical impact of ABCC 1 and ABCC 2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients. J Clin Pharm Ther. 2014;39(6):685-690. doi: 10.1111/jcpt.12197.

Franczyk B, Rysz J, Gluba-Brzózka A. Pharmacogenetics of drugs used in the treatment of cancers. Genes. 2022;13(2):311. doi: 10.3390/genes13020311.

Alsaedi AA, Younus MM. Gender differences in adverse drug reactions among adult patients reported to the Iraqi pharmacovigilance center. Iraqi J Pharm Sci. 2021;30(2):249-260. doi: 10.31351/vol30iss2pp249-260.

Peng N, Dou XL, Yu L, Qin YZ, Shi HX, Lai YY, et al. Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age. Zhonghua Xue Ye Xue Za Zhi. 2021;42(2):101-108. doi: 10.3760/cma.j.issn.0253-2727.2021.02.003.

Radhi KA, Matti BF, Hamzah IH, Alkasir R. The role of miRNA-150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients. Al-Mustansiriyah J Sci. 2023;34(1):16-22. doi: 10.29252/Mjs.25.1.

Mohammadi F, Shafiei M, Assad D, Rostami G, Hamid M, Foroughmand AM. Impact of ABCB1 gene polymorphisms and smoking on the susceptibility risk of chronic myeloid leukemia and cytogenetic response. Iran Biomed J. 2021;25(1):54. doi: 10.29252/ibj.25.1.54.

Marasca GS, Machado AL, Kretzmann Filho NA, Souza ACdS, Mattos AAd, Kliemann D, et al. Frequency of the mdr1 gene polymorphism rs1045642 (c3435t) in hcv-hiv co-infected patients. Arch Gastroenterol. 2016;53:246-249. doi: 10.1590/S0004-28032016000400007.

Abdullah D, Aloubaidy RM. Genetic polymorphism of caspase 8 and 9 in Iraq. Iraqi J Agricult Sci. 2022;53(3):505-514. doi: 10.36103/ijas.v53i3.1558.

Al-Yasiri YAH. Molecular study of BCR-ABL gene and genetic variations in chronic myeloid leukemia patients in Iraq. MSc Thesis. 2011. Available at: https://nahrainuniv.edu.iq/en/node/1472

Alaqidi AAH, Alwash MM. Association of GSTP1 Ile-105-Val gene polymorphism with response to treatment among Iraqi chronic myeloid leukaemia patients. Al Mustansiriyah J Pharm Sci. 2018;18(2):133-141. doi: 10.32947/ajps.v18i2.487.

Shaheed HS, Ali SH. Association of carnosinase-1 gene polymorphism with serum carnosine and carnosinease-1 isoform levels in type 2 diabetics with cardiovascular diseases in Iraq. Al-Rafidain J Med Sci. 2023;4:109-117. doi: 10.54133/ajms.v4i.121.

Dulucq S, Preudhomme C, Guilhot F, Mahon F-X. Response: is there really a relationship between multidrug resistance gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood. 2010;116(26):6145-6146. doi: 10.1182/blood-2010-08-298794.

Vivona D, Bueno CT, Lima LT, Hirata RDC, Hirata MH, Luchessi AD, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cell Mol Dis. 2012;48(2):132-136. doi: 10.3892/ol.2014.1857.